Interim results from the open-label extension of the CHAPTER-1 phase 2 trial support the long-term efficacy and safety of deucrictibant, an oral bradykinin B2 receptor antagonist, for hereditary angioedema prophylaxis
Interim results from the open-label extension of the CHAPTER-1 phase 2 trial support the long-term efficacy and safety of deucrictibant, an oral bradykinin B2 receptor antagonist, for hereditary angioedema prophylaxis
Interim results from the...